|
|
 |
|
Viewing report
|
|
|
|
European Heart Valve Markets
Frost & Sullivan, Aug 2001
Annuloplasty Procedures to Rise Rapidly
In 2000, nearly 78,400 heart valve repair procedures were conducted in Europe. Although the majority of these operations involved implanting mechanical or tissue replacement valves, the use of annuloplasty rings, which preserve existing valve structures, is on the rise. This method of treatment is less expensive than valve replacement and less traumatic for patients. As surgeons become more familiar with the procedure, a growing number willuse annuloplasty to repair, rather than replace, valves.
This Frost & Sullivan research analyses the European markets for mechanical and tissue heart valves, as well for annuloplasty rings. By targeting key drivers and restraints, and presenting expert forecasts for each segment within seven geographic markets, this report offers its users a comprehensive overview of the field.
New Treatments and Medications Impact Marketplace
Manufacturers across the three product segments are trying to tip the market balance in their favour, says the reports author. Historically, mechanical valves have dominated the marketplace, but as the quality of tissue valves increases and annuloplasty rings continue to garner interest, revenues for mechanical valves will decline.
Alternative therapy options are also gaining ground in valve replacement and repair product markets. New medications, which can enhance the pumping action of the heart, and competing surgical interventions, such as balloon catheterisation, could further seize revenues from valve and annuloplasty ring manufacturers. This study surveys the field of treatment options and
monitors industry changes, helping your company anticipate potential hurdles that may lay ahead.
Strategic Pricing Solutions Essential for Industry Winners
Cost containment in European healthcare systems will have a significant influence on heart valve markets. Because heart valve products are primarily purchased through public tenders, intensifying competition between manufacturers to win these tenders has resulted in price declines, says the author.
Only stentless valves will continue to attract premium pricing, but some participants have already begun to lower these prices as well to remain competitive. This report tracks pricing trends and assesses their impact on the industry, enabling your firm to stay one step ahead of uninformed competitors.
Market Participants
AorTech International Plc
ATS Medical, Inc.
CryoLife Europa Ltd.
Edwards Lifesciences Corp.
JOSTRA A
Labcor Laboratories
Medical Carbon Research Institute
Deutschland GmbH
Medical, Inc.
Medtronic Europe S
St. Jude Medical, Inc.
Sorin Biomedica Sp
Sulzer Carbomedics Ltd.
|
|
|
|
